Status:
COMPLETED
Comparison Between Hyperoncotic and Isooncotic Albumin to Support Blood Loss Replacement
Lead Sponsor:
Insel Gruppe AG, University Hospital Bern
Conditions:
Blood Loss, Surgical
Fluid Retention
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Fluid intravascular replacement is usually performed with either balanced crystalloids or iso-oncotic colloids, (synthetic colloids, plasma and 5% albumin). Doubts have been raised about synthetic col...
Detailed Description
Bladder cancer occurs mainly in old comorbid patients. The standard treatment of localized muscle invasive bladder cancer is pelvic lymph node dissection and radical cystectomy with urinary diversion....
Eligibility Criteria
Inclusion
- Non emergent radical cystectomy with urinary diversion
- Adult: older than 18 years
- Written informed consent
Exclusion
- Contraindications to the class of drugs under study (i.e: known hypersensitivity/ allergy to class of drugs or to the investigational product).
- Renal insufficiency: GFR: \<60ml/min/1.73m2 (KDIGO Clinical Practice Guideline for Acute Kidney Injury, stage 3 and over).
- History of heart failure.
- Use of diuretic treatment.
- Women who are pregnant or breast feeding (exclusion of surgery per se).
- Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant.
- Enrolment of the investigator, his/her family members, employees and other dependent persons.
Key Trial Info
Start Date :
May 25 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 10 2023
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT05391607
Start Date
May 25 2022
End Date
April 10 2023
Last Update
April 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Patrick Wuethrich, Department of Anaesthesiology and Pain Therapy, University Hospital Bern Inselspital Bern
Bern, Canton of Bern, Switzerland, 3010